DXCM Stock Forecast 2025-2026
Distance to DXCM Price Targets
DXCM Price Momentum
10 Quality Stocks Worth Considering Now
Researching DexCom (DXCM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on DXCM and similar high-potential opportunities.
Latest DXCM Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, DXCM has a bullish consensus with a median price target of $100.00 (ranging from $80.00 to $115.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $70.78, the median forecast implies a 41.3% upside. This outlook is supported by 23 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Issie Kirby at Redburn Atlantic, projecting a 62.5% upside. Conversely, the most conservative target is provided by Larry Biegelsen at Wells Fargo, suggesting a 13.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DXCM Analyst Ratings
DXCM Price Target Range
Latest DXCM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DXCM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2025 | Mizuho | Anthony Petrone | Outperform | Initiates | $85.00 |
| Mar 4, 2025 | Citigroup | Joanne Wuensch | Buy | Maintains | $104.00 |
| Feb 14, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $103.00 |
| Feb 14, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $82.00 |
| Feb 3, 2025 | Redburn Atlantic | Issie Kirby | Buy | Upgrade | $115.00 |
| Jan 16, 2025 | Baird | Jeff Johnson | Outperform | Upgrade | $104.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $91.00 |
| Dec 11, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $94.00 |
| Dec 9, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $99.00 |
| Oct 25, 2024 | Raymond James | Jayson Bedford | Strong Buy | Maintains | $99.00 |
| Oct 25, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $90.00 |
| Oct 25, 2024 | Leerink Partners | Mike Kratky | Outperform | Maintains | $87.00 |
| Oct 25, 2024 | JP Morgan | Robbie Marcus | Neutral | Maintains | $85.00 |
| Oct 25, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $115.00 |
| Oct 25, 2024 | Oppenheimer | Steven Lichtman | Outperform | Maintains | $105.00 |
| Oct 25, 2024 | Bernstein | Lee Hambright | Outperform | Maintains | $86.00 |
| Oct 8, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $120.00 |
| Aug 26, 2024 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $90.00 |
| Aug 23, 2024 | Stifel | Mathew Blackman | Buy | Maintains | $100.00 |
| Aug 5, 2024 | Baird | Jeff Johnson | Neutral | Maintains | $82.00 |
Dexcom Inc. (DXCM) Competitors
The following stocks are similar to DexCom based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dexcom Inc. (DXCM) Financial Data
Dexcom Inc. has a market capitalization of $26.22B with a P/E ratio of 47.1x. The company generates $4.03B in trailing twelve-month revenue with a 14.3% profit margin.
Revenue growth is +7.6% quarter-over-quarter, while maintaining an operating margin of +17.0% and return on equity of +27.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Dexcom Inc. (DXCM) Business Model
About Dexcom Inc.
Develops continuous glucose monitoring systems.
Dexcom Inc. generates revenue by designing, manufacturing, and selling advanced continuous glucose monitoring (CGM) systems primarily for individuals with diabetes. The company leverages innovative technology and data analytics to provide real-time glucose readings, enhancing patient care and enabling users to manage their health effectively.
Founded in 1999 and based in San Diego, California, Dexcom is a leader in the digital health solutions market, focusing on improving the quality of life for diabetes patients through its cutting-edge monitoring devices. The company plays a significant role in healthcare by offering alternatives to traditional testing methods and continuously innovating its product offerings.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
10,200
CEO
Mr. Kevin Ronald Sayer
Country
United States
IPO Year
2005
Website
www.dexcom.com/globalDexcom Inc. (DXCM) Latest News & Analysis
Latest News
Kuehn Law is investigating DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties by officers and directors related to misrepresentation of 2024 revenue forecasts.
Allegations of fiduciary duty breaches and potential revenue misrepresentation at DexCom can lead to legal liabilities, impacting stock performance and investor sentiment.
Bragar Eagel & Squire is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) related to a class action filed on August 21, 2024, regarding possible breaches of fiduciary duties.
The investigation into DexCom's board regarding potential fiduciary breaches could impact stock performance, investor confidence, and legal liabilities, affecting long-term shareholder value.
Johnson Fistel is investigating DexCom, Inc. (NASDAQ: DXCM) for possible breaches of fiduciary duties by its board and executives, related to misleading statements about its expansion strategy.
The investigation into DexCom's executives for potential fiduciary breaches could lead to legal repercussions, impacting the company's reputation and stock price, affecting investor confidence.
Johnson & Johnson and Eli Lilly commented on Trump's pharmaceutical tariffs, while Dexcom received FDA approval for its glucose monitoring system.
Pharmaceutical tariffs may impact drug pricing and margins for Johnson & Johnson and Eli Lilly, affecting stock performance. Dexcom's FDA approval could boost its market position and revenue potential.
DXCM has received FDA clearance for its G7 15-Day continuous glucose monitor, noted for its longevity and accuracy, which may enhance convenience and access in diabetes care.
FDA clearance for DXCM's G7 CGM boosts its market position, potentially increasing sales and user adoption in diabetes care, which can drive stock performance and investor confidence.
DexCom plans to launch its G7 15 Day system in the second half of 2025.
DexCom's G7 system launch timeline signals potential revenue growth and market expansion, impacting stock performance and competitive positioning in the diabetes management sector.
Frequently Asked Questions About DXCM Stock
What is Dexcom Inc.'s (DXCM) stock forecast for 2025?
Based on our analysis of 31 Wall Street analysts, Dexcom Inc. (DXCM) has a median price target of $100.00. The highest price target is $115.00 and the lowest is $80.00.
Is DXCM stock a good investment in 2025?
According to current analyst ratings, DXCM has 23 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $70.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DXCM stock?
Wall Street analysts predict DXCM stock could reach $100.00 in the next 12 months. This represents a 41.3% increase from the current price of $70.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dexcom Inc.'s business model?
Dexcom Inc. generates revenue by designing, manufacturing, and selling advanced continuous glucose monitoring (CGM) systems primarily for individuals with diabetes. The company leverages innovative technology and data analytics to provide real-time glucose readings, enhancing patient care and enabling users to manage their health effectively.
What is the highest forecasted price for DXCM Dexcom Inc.?
The highest price target for DXCM is $115.00 from Issie Kirby at Redburn Atlantic, which represents a 62.5% increase from the current price of $70.78.
What is the lowest forecasted price for DXCM Dexcom Inc.?
The lowest price target for DXCM is $80.00 from Larry Biegelsen at Wells Fargo, which represents a 13.0% increase from the current price of $70.78.
What is the overall DXCM consensus from analysts for Dexcom Inc.?
The overall analyst consensus for DXCM is bullish. Out of 31 Wall Street analysts, 23 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $100.00.
How accurate are DXCM stock price projections?
Stock price projections, including those for Dexcom Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.